Lung Cancer Trials Ask AI to find trials
CompletedNot applicableNCT00003329
Official study title

Identification of Genes Associated With Cancer in Patients and Siblings Who Have Cancer

Study summary

RATIONALE: Identification of genes that may be associated with developing certain types of cancer may someday provide important information about a person's risk of getting cancer. PURPOSE: This clinical trial is studying to see if certain genes may be associated with cancer in patients with cancer of the breast, prostate, lung, or colon and siblings of these patients.

Ask AI to explain this study
Start here

Key things to know

Main goalNot specified

This describes the study’s primary purpose.

What is being studiedgene mapping

The study team can explain what participation involves.

Who it may be forBreast Cancer · Colorectal Cancer

These are broad labels—not an eligibility decision.

Checked against the public recordLast updated Jun 15, 2023 · Source: ClinicalTrials.gov

Is enrollment open?Completed

Ask the study team to confirm whether enrollment is open.

What kind of study?Not applicable

Observational

Where is it offered?32 U.S. locations

Locations may change over time.

Who runs it?Eastern Cooperative Oncology Group

Study sponsor

01
Study overview

What this study is about

Purpose
Not specified
Study type
Observational
Phase
Not applicable
Sponsor
Eastern Cooperative Oncology Group
Interventions being studied
Genetic: gene mapping
02
Explore related studies

How this study is categorized

These labels come from structured fields and exact terms in the public record.

03
Public criteria

Who may be able to participate

The sponsor separates these requirements into two groups. You do not need to interpret them alone—use them to guide a conversation with the study team.

Requirements people may need to meetInclusion criteria
  • DISEASE CHARACTERISTICS:
  • Histologically confirmed colon, lung, prostate, or invasive breast cancer
  • No ductal or lobular carcinoma in situ of the breast only
  • Patient and natural full sibling must have (or have had) cancer of the same type
  • Participants in E-3Y92 not eligible
  • Hormone receptor status:
  • Not specified PATIENT CHARACTERISTICS: Age:
  • Not specified Menopausal status:
  • Not specified Performance status:
  • Not specified Life expectancy:
  • Not specified Hematopoietic:
  • Not specified Hepatic:
  • Not specified Renal:
  • Not specified PRIOR CONCURRENT THERAPY: Biologic therapy
  • Not specified Chemotherapy
  • Not specified Endocrine therapy
  • Not specified Radiotherapy
  • Not specified Surgery
  • Not specified

Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.

04
Study sites

U.S. locations

  • Lucy Curci Cancer Center at Eisenhower Memorial Hospital and Medical CenterRancho Mirage, California
  • Front Range Cancer SpecialistsFort Collins, Colorado
  • Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community HospitalBoca Raton, Florida
  • Lakeland Regional Cancer Center at Lakeland Regional Medical CenterLakeland, Florida
  • Robert H. Lurie Comprehensive Cancer Center at Northwestern UniversityChicago, Illinois
  • Veterans Affairs Medical Center - Chicago Westside HospitalChicago, Illinois
  • Evanston Northwestern Healthcare - Evanston HospitalEvanston, Illinois
  • Hematology Oncology Associates - SkokieSkokie, Illinois
  • Siouxland Hematology-Oncology Associates, LLPSioux City, Iowa
  • Mercy Medical Center - Sioux CitySioux City, Iowa
  • St. Luke's Regional Medical CenterSioux City, Iowa
  • Green Bay Oncology, Limited - EscanabaEscanaba, Michigan

Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jun 15, 2023. Always confirm current availability with the study team.

View original record ↗